Brains from patients with Alzheimer disease (AD) show a disruption in the metabolism of iron, such that there is an accumulation of iron in senile plaques, and an altered distribution of iron transport and storage proteins. One of the earliest events in AD is the generation of oxidative stress, which may be related to the generation of free radicals by the excess iron that is observed in the disease. Iron has also been shown to mediate the in vitro toxicity of amyloid-ß peptide, and the presence of iron in most in vitro systems could underlie the toxicity that is normally attributed to amyloid-ß in these studies. In contrast, several recent studies have suggested that amyloid-ß may decrease oxidative stress and decrease the toxicity of iron. Continued examination of the complex interactions that occur between iron and amyloid-ß may assist in the elucidation of the mechanisms that underlie the neurodegeneration that leads to dementia in AD.
Alzheimer disease (AD) is a progressive form of dementia that commonly occurs in the aged population. The brains from patients with AD contain numerous senile plaques; extracellular proteinaceous deposits that are closely associated with the neurodegeneration seen in these brains. It has been suggested that the presence of high numbers of senile plaques underlies the neurodegeneration and resulting dementia seen in AD and, more specifically, that amyloid-ß peptide, the major component of senile plaques, is the primary cause of toxicity in AD [e.g., 1]. Nonetheless, there are many other components within senile plaques in addition to amyloid-ß, and some of these factors could be responsible for plaque-associated neurotoxicity. One such factor is iron, which has been observed within senile plaques along with amyloid-ß [2, 3] .
The amount of iron reported to be present in senile plaques is 52.5 Ìg/g tissue, which would equate to a con-centration of approximately 1 mM on a weight:volume ratio [4] . It has been established that elevated concentrations of iron are highly toxic through the generation of reactive oxygen species via the Fenton reaction [5] . Thus, it is important to note that the iron in senile plaques is redox-active and capable of producing reactive oxygen species [2, 6] . It has also been shown that injection of 1 mM ferric iron into rat cerebral cortex induces a large amount of neuronal loss at the site of the injection [7] . Together these findings indicate that not only is iron present within AD plaques at potentially highly toxic concentrations, but that its presence in a redox-active form could lead to large amounts of oxidative damage. However, as shown later, amyloid-ß may also sequestrate iron and, like many chelators, such binding can either enhance or diminish redox activity dependent upon the circumstances. In this regard, while markers of neuronal oxidation are seen in the brains of AD patients very early in the disease, such oxidative stress decreases as a direct function of increased amyloid-ß burden [8] .
In addition to the presence of high concentrations of iron in senile plaques, there is other evidence that the metabolism of iron is disrupted in AD. For instance, the iron-transport protein transferrin is diffusely located within senile plaques, instead of being present in its regular location in the cytosol of oligodendrocytes [3] , suggesting that it may become trapped within plaques when it is attempting to transport iron between cells. Melanotransferrin, which mediates iron uptake by cells, is abnormally expressed in AD within reactive microglial cells that are associated with senile plaques [9] . The distribution of the iron-storage protein ferritin is also altered in AD and is expressed within microglial cells that are present both in and around senile plaques [3, [10] [11] [12] . The level of expression of these proteins that are involved in iron storage and transport is controlled by iron regulatory proteins (IRPs). Thus it is interesting to note that there are significant alterations in IRPs in AD, which parallel the pathological lesions of the disease [13] , and the alterations in iron distribution [2] . There also exist differences in the complexes formed by IRP and the iron response element in AD brains which could lead to disruptions in the sequestration and storage of iron [14] . This corresponds with the report from Lovell et al. [4] that in addition to the accumulation of iron in senile plaques, the amount of iron present in the AD neuropil is twice that seen in the neuropil in non-demented brains.
While there is abundant evidence of disruptions of iron metabolism in the AD brain, it should also be noted that there is an increased amount of copper and zinc present within the neuropil, and within plaques [4] . Amyloid-ß also binds copper and zinc with high affinity [15, 16] , and the binding of these metals occurs at the histidine residues that are present on the peptide in a similar manner seen with iron [15, 17] .
Iron Mediates Amyloid-ß Toxicity
The disruption of iron metabolism in the AD brain suggests that iron may produce some of the neurodegeneration that is observed in AD. Nonetheless, the major focus of research into AD neuropathogenesis has involved studying the toxicity of the amyloid-ß peptide. This intense focus has in part been derived from numerous studies reporting that the addition of amyloid-ß to cultured cells results in toxicity and subsequent cell death [e.g., 18, 19] . The toxicity of amyloid-ß reported from in vitro studies is in part due to the conformational status of the peptide, with amyloid-ß reportedly being most toxic when it is in an aggregated form [20] . Several types of events can promote the aggregation of amyloid-ß, including the presence of an acidic environment as well as an interaction with metal ions [15, 21] . Amyloid-ß binds iron [22] , and promotes aggregation [23, 24] . This altered conformational status of the peptide should promote an increased neurotoxicity of amyloid-ß.
The ability of iron to alter the properties of amyloid-ß has been observed in in vitro studies and may underlie the toxicity that has been reported. A defining study by Schubert and Chevion [25] demonstrated that amyloid-ß is only toxic to cultured cells when iron is present within the culture media, indicating that the iron influences the toxicity of amyloid-ß, and indeed may produce an artefactual cytotoxicity that is related to the iron rather than the amyloid-ß itself. This finding received support from a subsequent study where it was shown that pre-treatment of amyloid-ß with deferoxamine significantly reduced the neuronal loss after amyloid-ß was added to cultured neurons, showing that synthetic amyloid-ß preparations also appear to be contaminated with iron [26] . Under these conditions, amyloid-ß toxicity may be caused by the promotion of aggregation by iron, however there may also be a direct production of free radicals by the iron. For instance, the binding of iron to amyloid-ß causes the generation of hydrogen peroxide [27] . It has also been shown that when iron and amyloid-ß are mixed and then added to brain homogenates, reactive oxygen species are produced [28] . Furthermore, recent studies have demonstrated that the previously reported spontaneous produc-tion of radicals by amyloid-ß [29] [30] [31] may be attributed to low-level contamination with iron [32] [33] [34] . Lastly, it has been observed that the interaction of amyloid-ß and iron generates advanced glycation end-products (AGEs) [35] , which are present in senile plaques [36, 37] and are toxic to cells via the production of free radicals [38] .
Other Interactions between Amyloid-ß and Iron
There is now well-documented literature demonstrating that the interaction of iron with amyloid-ß can lead to toxicity. In an in vivo model, it has recently been shown that when amyloid-ß is co-injected with iron into rat cerebral cortex, there is significantly more neuronal loss than is produced by injection of pure amyloid-ß peptide [39] . Nonetheless, an important finding of these studies is that the presence of amyloid-ß decreases the neuronal loss that would normally be seen around an injection of iron, suggesting that amyloid-ß may play a role in decreasing oxidative stress [39, 40] . This suggestion is consistent with the observation that oxidative stress in the human brain is inversely correlated with amyloid-ß load [8, 41] , and is further supported by studies showing that the oxidation of lipoproteins in the cerebrospinal fluid is inversely correlated with the amount of amyloid-ß [42, 43] .
The concept that amyloid-ß protects against oxidative stress that may occur due to excess iron in AD is in contrast to the previously mentioned studies that reported that the interaction between iron and amyloid-ß produces toxicity. This suggests that there is a complex interaction between iron and amyloid-ß within the central nervous system such that when iron interacts with amyloid-ß it may increase the toxicity associated with amyloid-ß, yet the presence of amyloid-ß may decrease the pro-oxidative effects of iron. The co-localization of amyloid-ß and iron within the extracellular space of the brain may be informative of the pathogenesis of AD.
Conclusions
While the majority of researchers investigating AD pathogenesis favor amyloid-ß as the neurotoxic culprit in AD, our view is more circumspect and we consider that there may be another cause for the characteristic neurodegeneration. Oxidative damage is a very early event in the AD brain [8] , and the concept that amyloid-ß can reduce this damage (as discussed above) indicates a potential role for amyloid-ß as an anti-oxidant, as we have suggested elsewhere [44] [45] [46] [47] [48] . Thus, if excess iron plays a role in the neuropathogenesis of AD, then the removal of this iron may be beneficial in the treatment of AD. Clinical studies that have administered deferoxamine to AD patients as a potential therapeutic agent have found that during 2 years of treatment there is a significant slowing of disease progression [49, 50] . However, given that oxidative stress occurs long before the clinical symptoms of AD are observed, therapeutic intervention aimed at removing iron from AD patients may be administered too late to be able to reverse the effects of excess iron. Nonetheless, these therapies may still have some benefit in preventing the continued accumulation of excess toxic iron.
